NEW YORK (GenomeWeb) – Sophia Genetics said today that it has closed on a $77 million Series E round of venture capital, led by new investor Generation Investment Management, with participation from Idinvest Partners and previous Sophia equity backers Balderton Capital and Alychlo.
Sophia, which now has co-headquarters in Boston and Lausanne, Switzerland, said that it will apply much of the new funding to expand its US presence by growing its workforce and marketing to more American hospitals.
"With Generation’s support, we will enable the more rapid adoption of data-driven medicine technology in healthcare for the benefit of patients worldwide," added Sophia CEO and Founder Jurgi Camblong.
Sophia Genetics last landed new funding in a $30 million Series D round that closed in September 2017. To date, the company has raised $140 in private equity.